Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Current Deferred Revenue: 2009-2025

Historic Current Deferred Revenue for China Pharma Holdings (CPHI) over the last 16 years, with Sep 2025 value amounting to $120,912.

  • China Pharma Holdings' Current Deferred Revenue rose 385.20% to $120,912 in Q3 2025 from the same period last year, while for Sep 2025 it was $120,912, marking a year-over-year increase of 385.20%. This contributed to the annual value of $162,208 for FY2024, which is 79.22% up from last year.
  • China Pharma Holdings' Current Deferred Revenue amounted to $120,912 in Q3 2025, which was up 55.65% from $77,683 recorded in Q2 2025.
  • Over the past 5 years, China Pharma Holdings' Current Deferred Revenue peaked at $572,013 during Q1 2021, and registered a low of $24,920 during Q3 2024.
  • Moreover, its 3-year median value for Current Deferred Revenue was $112,357 (2024), whereas its average is $106,746.
  • Its Current Deferred Revenue has fluctuated over the past 5 years, first plummeted by 85.52% in 2024, then skyrocketed by 385.20% in 2025.
  • Over the past 5 years, China Pharma Holdings' Current Deferred Revenue (Quarterly) stood at $210,028 in 2021, then skyrocketed by 147.73% to $520,295 in 2022, then plummeted by 82.60% to $90,507 in 2023, then skyrocketed by 79.22% to $162,208 in 2024, then spiked by 385.20% to $120,912 in 2025.
  • Its Current Deferred Revenue was $120,912 in Q3 2025, compared to $77,683 in Q2 2025 and $114,435 in Q1 2025.